Results from the Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure (DAPA-HF) showed that dapagliflozin, an SGLT2 inhibitor, reduced the incidence of type 2 diabetes by 32% in patients with heart failure but without diabetes at baseline. “While the major…

Bruce A. Buckingham, MD, and three other experts reviewed results from four new clinical trials examining the next generation of automated insulin delivery systems for type 1 diabetes patients during the Scientific Sessions. New technology holds promise for easing the lifestyle complications of type 1 diabetes by improving glycemic control, particularly overnight, Dr. Buckingham said.

Several researchers from the Diabetes Prevention Program Outcomes Study (DPPOS) shared new data on clinical outcomes from the largest and longest follow-up to the Diabetes Prevention Program study during the Scientific Sessions. DPPOS Chair David M. Nathan, MD, said that while the benefits of the original interventions have decreased over time, both the metformin and…

Investigators from The Environmental Determinants of Diabetes in the Young (TEDDY) study presented the latest results from the ongoing study during the Scientific Sessions. TEDDY Co-Chair Marian Rewers, MD, PhD, reviewed research into genetic and clinical markers that indicates that screening for islet autoimmunity in high-risk youth should start in the first two years of…

Five investigators from the SEARCH for Diabetes in Youth Study reviewed critical lessons from two decades of surveillance and observational research into youth-onset diabetes during the Scientific Sessions. “SEARCH has identified social, behavioral, and psychological correlates that are linked to pediatric diabetes management, the number of which further demonstrate the complexity of this disease and…

The Restoring Insulin Secretion (RISE) Study, which tested interventions designed to preserve or improve beta-cell function in prediabetes and early type 2 diabetes, offers important insight into differences between adults and youth in the onset and progression of type 2 diabetes. Given the differences in the two populations, investigators like Kristen Nadeau, MD, MS, are…

Ongoing research into the mechanisms of inter-organ crosstalk, including the key signaling pathways involved in obesity and diabetes, may provide targets for new therapies to treat, and potentially even prevent, these and other metabolic disorders, according to Jiandie Lin, PhD, recipient of the 2020 ADA Outstanding Scientific Achievement Award.

Investigators from the United States and Europe came together Monday for a symposium jointly sponsored by the ADA and the European Association for the Study of Diabetes. During the virtual presentation, R. Paul Wadwa, MD, reviewed data on closed-loop systems approved by the U.S. Food and Drug Administration, as well as data on systems still…

Research into the connection between diabetes and pancreatic ductal adenocarcinoma (PDAC) indicates that new-onset hyperglycemia could offer earlier warning of PDAC development, according to Suresh T. Chari, MD. Dr. Chari and three other researchers discussed endocrine/exocrine interactions in diabetes during a Monday morning symposium.

Two cardiologists—Mikhail Kosiborod, MD, and Darren K. McGuire, MD, MHSc—faced off in a virtual debate examining whether sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists should have a more prominent role in cardiovascular interventions on Monday during the Scientific Sessions.